BMS-936559, a fully human IgG4 antibody that blocks PD-L1, has been shown to induce objective responses in melanoma, NSCLC, and certain other solid tumours in Phase I clinical trials34, 35. The gene discussed is CD274; the disease is non-small cell lung carcinoma.